ImmunityBio (IBRX) Intangibles (2014 - 2024)

ImmunityBio (IBRX) has reported Intangibles for 10 consecutive years, with $16.1 million the latest figure, recorded in Q2 2024.

• In Q2 2024, Intangibles fell 15.45% year-over-year to $16.1 million; the TTM figure through Jun 2024 stood at $16.1 million (down 15.45% YoY), while the FY2023 annual figure was $17.1 million, down 14.55% from the prior year.
• Intangibles eased to $16.1 million in Q2 2024 per IBRX's latest filing, from $16.6 million in the prior quarter.
• Across five years, Intangibles topped out at $22.3 million in Q1 2022 and bottomed at $1.4 million in Q4 2021.
• Historically, Intangibles has averaged $13.2 million across 5 years, with a median of $17.1 million in 2023.
• Annual changes were most pronounced in 2022 — Intangibles jumped 1454.17% — and 2024, when it fell 15.45%.
• ImmunityBio's Intangibles stood at $1.5 million in 2020, then slipped by 2.94% to $1.4 million in 2021, then surged by 1308.66% to $20.0 million in 2022, then declined by 14.55% to $17.1 million in 2023, then dropped by 6.06% to $16.1 million in 2024.
• Business Quant data shows IBRX's Intangibles at $16.1 million in Q2 2024, $16.6 million in Q1 2024, and $17.1 million in Q4 2023.